Abiopharma

🔍 Hussain Aamir (Executive)

Company: Liberty Latin America Ltd. (LILA)

Report Date: 2026-06-30

Detailed Transactions and Holdings:

• Acquired 833 shares of Class C Common Shares (Direct)
  Date: 2026-06-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 394,587.00 | transaction_form_type: 5 | Footnotes: F1
• Acquired 2,500 shares of Class C Common Shares at $7.32 per share (Direct)
  Date: 2026-06-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 397,087.00 | transaction_form_type: 5 | Footnotes: F2, F3
• Acquired 83 shares of Series A Preference Shares (Direct)
  Date: 2026-06-30 | Code: J | equity_swap_involved: 0 | shares_owned_after: 60,853.00 | transaction_form_type: 5 | Footnotes: F4

Footnotes:

• F1: These shares were acquired pursuant to the "match benefit" of ESPP in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
• F2: These shares were acquired under the Liberty Latin America Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
• F3: The Employee Stock Purchase Plan's "look-back" feature was used to determine the purchase price for these shares. The "look-back" feature compares the closing price of the Issuer's Class C common shares on the first and last trading days of the January 1 - June 30, 2026 contribution period, with the lower of the two being used to determine the purchase price.
• F4: These Preferred Shares were acquired pursuant to the "match benefit" of the Liberty Latin America Employee Stock Purchase Plan and were issued at a rate of 0.10 Preferred Shares for each matching share of the Issuer's common stock credited to the reporting person under the plan. This transaction was exempt under Rule 16a-9.
• REMARKS: The trading symbols for the Issuer's classes of common shares are LILA, LILAB, and LILAK, and the trading symbol for the Issuer's Series A Preference Shares is LILAP.